At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 56 enrolled
Drug / intervention
Albuterol/salbutamol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 4 clinical trial evaluating Albuterol/salbutamol and Ipratropium for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 56 participants across 2 sites in 2 countries.
Detailed Summary
The objective of this study is to assess the daily variation in bronchodilator response to an inhaled short acting beta2-agonist (albuterol/salbutamol) and an inhaled short acting anticholinergic (ipratropium) individually and when used in combination in subjects with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedSep 2012
Primary CompletionOct 2012
Study CompletionOct 2012
TodayJul 2026
First PostedSep 24, 2012
Enrollment StartJul 23, 2012
Primary CompletionOct 1, 2012
Study CompletionOct 22, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.8 years ago
Interventions
Albuterol/salbutamoldrug
Albuterol/salbutamol (daily)
Ipratropiumdrug
Ipratropium (daily)